Ryan D. Gentzler, MD

Photo of Ryan Gentzler

PRIMARY APPOINTMENT:

Associate Professor, Medicine: Hematology and Oncology

CONTACT:

UVA Hematology/Oncology
Po Box 800716
Charlottesville, VA 22908
Telephone: 434.924.9333
Fax: 434.244.7526
Email: rg2uc@virginia.edu

EDUCATION AND TRAINING:

Clinical Fellowship, Hematology-Oncology, Northwestern Memorial Hospital, Chicago, IL
MD, Temple University School of Medicine
Residency, Internal Medicine, Thomas Jefferson University Hospital, Philadelphia, PA

RESEARCH INTERESTS:

Lung cancer, novel therapies, cancer immunology, and targeted therapy.

RESEARCH SUMMARY:

Lung cancer, novel therapies, cancer immunology, and targeted therapy.

SELECT PUBLICATIONS:

Devitt M, Hall R, Gentzler RD, Peripheral Blood Cell-Free DNA to Monitor Mutational Response in Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer., 2017; International journal of radiation oncology, biology, physics. 98(1) 250. PMID: 28587042
Gentzler RD, Mohindra NA, Hanna N, Chae YK, Jalal SI, Hall R, Villaflor VM, Reckamp KL, Koczywas M, Sullivan D, Wood L, Patel JD, Carboplatin/nab-Paclitaxel and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): Phase 1 Results., 2017; International journal of radiation oncology, biology, physics. 98(1) 236. PMID: 28587008
Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad MM, Fiore J, Ge Y, Raftopoulos H, Gandhi L, Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomized, phase 2 cohort of the open-label KEYNOTE-021 study., 2016; The Lancet. Oncology. 17(11) 1497-1508. PMID: 27745820
Gentzler R, Hall R, Kunk PR, Gaughan E, Dillon P, Slingluff CL, Rahma OE, Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors., 2016; Immunotherapy. 8(5) 583-600. PMID: 27140411
Hall RD, Le TM, Haggstrom DE, Gentzler RD, Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC)., 2015; Translational lung cancer research. 4(5) 515-23. PMID: 26629420 | PMCID: PMC4630516
Gentzler RD, Johnson ML, Complex decisions for first-line and maintenance treatment of advanced wild-type non-small cell lung cancer., 2015; The oncologist. 20(3) 299-306. PMID: 25660158 | PMCID: PMC4350796